Horizon Therapeu
Stock
Stock
ISIN: IE00BQPVQZ61
Ticker: HZNP
IE00BQPVQZ61
HZNP
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Horizon Therapeu?
Horizon Therapeu's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 1.65. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Horizon Therapeu's stock?
Currently, 1 analysts cover Horizon Therapeu's stock, with a consensus target price of €102.74. Analyst ratings provide insights into the stock's expected performance.
What is Horizon Therapeu's revenue over the trailing twelve months?
Over the trailing twelve months, Horizon Therapeu reported a revenue of €3.21B.
What is the EBITDA for Horizon Therapeu?
Horizon Therapeu's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is €817.67M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Horizon Therapeu?
Horizon Therapeu has a free cash flow of €845.20M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Horizon Therapeu have, and what sector and industry does it belong to?
Horizon Therapeu employs approximately 2,115 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- EPS (TTM)
- 1.65
- Revenue (TTM)
- €3.21B
- EBITDA (TTM)
- €817.67M
- Free Cashflow (TTM)
- €845.20M
Analyst Ratings
The price target is €102.74 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
- Employees
- 2,115
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- IE00BQPVQZ61
- Primary Ticker
- HZNP
Knockouts
LSX Data · Fundamentals & EOD data from FactSet